Detailed narrative
New CEO Vision and Strategy
Srishti Gupta, in her first earnings call as CEO, outlined NovaBridge's vision to bridge the gap between exceptional science and patient impact. The company aims to identify promising new medicines, advance them efficiently, and pursue optimal development, financing, or partnering strategies. This approach positions NovaBridge at the intersection of innovation and translation, particularly leveraging opportunities from Asia and focusing on disciplined capital allocation.
Givastomig Oncology Program Progress
The lead oncology program, givastomig, for HER2-negative CLDN18.2 positive PD-L1-positive gastroesophageal cancer, has shown rapid progress. During H1 2026, NovaBridge reported updated Phase Ib results, initiated a global randomized Phase II study, and achieved significant regulatory milestones. The FDA confirmed eligibility for an accelerated approval pathway and granted Fast Track designation in June, increasing confidence in the program's registrational path. Updated Phase Ib dose expansion data is expected at ESMO in October, with Phase III initiation targeted as early as Q4 2026.
VIS-101 Ophthalmology Program Development
VIS-101, advanced through Visara, NovaBridge's majority-owned ophthalmology subsidiary, is designed to address unmet needs in retinal vascular disease by improving durability and reducing treatment burden. Positive Phase IIa top-line results earlier this year demonstrated improvements in visual acuity, reductions in retinal thickness, durable treatment responses, and a favorable safety profile. The company is preparing to initiate a Phase IIb study in H2 2026 to define the optimal dose and advance towards global Phase III development.
Financial Strength and Capital Allocation
NovaBridge reported a strong financial position with approximately $216 million in cash and investments as of June 30, 2026, and a debt-free balance sheet. This financial flexibility is expected to support the company through critical clinical and strategic inflection points, including the anticipated Phase III interim data readout for givastomig in 2028. The company emphasizes disciplined capital allocation, deploying capital thoughtfully while maintaining flexibility for financing, partnering, or corporate structures best suited for each asset.
Future Growth Platforms and European Market Strategy
The company is exploring future growth platforms, including addressing 'European gaps' and women's health. For Europe, the strategy involves combining NovaBridge's business development and clinical development expertise with European commercial organizations. The goal is to bring innovative assets to market by leveraging data generated outside Europe, utilizing efficient regulatory pathways, and potentially low-cost manufacturing to fit national health systems, focusing on unmet needs where current standards of care are less advanced.
Asset Screening and Commercialization Focus
NovaBridge's asset screening process has evolved to prioritize clinical development programs and commercial viability. The company now rigorously evaluates what is required to reach the next value inflection point and achieve registration, alongside a clear pathway for getting therapies to patients. This includes assessing differentiation for physicians and payers, navigating health systems, and understanding prior authorization barriers, reflecting a strong focus on commercialization potential from early stages.